• Chronic lymphocytic leukemia

Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction. She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at DFCI. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.

Her interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has been instrumental in the clinical development of idelalisib and ibrutinib, leading to their regulatory approvals in CLL. Her genomics work has characterized the somatic mutation profile of CLL, and she is now particularly interested in the implementation of genomic technology in the clinic. She also has a longstanding research interest in the inherited predisposition to CLL. To date she has published about 250 papers in the scientific literature, predominantly in CLL. In 2014 she was the recipient of two awards from DFCI, the Clinical Innovation Award, as well as the George Canellos Award. She is a member of the International Workshop on CLL (iwCLL) and enjoys a worldwide reputation as a CLL expert having made the Highly Cited Researchers list by Clarivate, with multiple papers ranking in the top 1% by citations for their field and year of publication.